Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.

Lin J, Gill OBQ, Zheng S, Niu R, Hong L, Teng Y.

Open source

DOI
10.62347/dqmq7497
Published
2026-09-15
Container
Am J Cancer Res
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.62347/dqmq7497,
  title = {Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.},
  author = {Lin J and  Gill OBQ and  Zheng S and  Niu R and  Hong L and  Teng Y.},
  year = {2026},
  journal = {Am J Cancer Res},
  doi = {10.62347/dqmq7497},
  url = {https://doi.org/10.62347/dqmq7497}
}

RIS

TY  - JOUR
TI  - Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.
AU  - Lin J
AU  -  Gill OBQ
AU  -  Zheng S
AU  -  Niu R
AU  -  Hong L
AU  -  Teng Y.
PY  - 2026
JO  - Am J Cancer Res
DO  - 10.62347/dqmq7497
UR  - https://doi.org/10.62347/dqmq7497
ER  - 

APA

J, L., OBQ, G., S, Z., R, N., L, H., & Y., T. (2026). Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.. Am J Cancer Res. https://doi.org/10.62347/dqmq7497

Source records